AI-Enabled Ejection Fraction Assessment Using COR ECG Wearable Monitor

This study is looking at a new way to measure how well your heart pumps blood, called ejection fraction (EF). It uses an artificial intelligence (AI) software with the Peerbridge COR™ ECG Wearable Monitor, a device you wear. The goal is to see if this AI software can accurately tell the severity of your heart's pumping ability, similar to how an ultrasound (echocardiography) does. This could offer an easier, more accessible way to check heart function. We are looking for 2000 participants aged 18 or older who are able to wear a Holter monitor. The study will measure the agreement between the AI software's results and ultrasound results over about 9 months.

Study design
This is an observational study involving 2000 participants. It aims to compare the AI software's results with standard ultrasound measurements.
What's involved
You would wear the Peerbridge COR™ device and sit for 15 minutes during the ECG acquisition. The study will last for an average of 9 months.
Compensation
Not stated in the trial record.
Follow-up
The primary measurement will be taken through study completion, which is an average of 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06699056

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Recruiting
Not specifiedAges 18+Observational
Peerbridge Health, Inc
~2,000 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:15-minutes of sitting during COR ECG Acquistion

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Agreement of CorEFS Software EF Severity Categories Using Peerbridge COR™ ECG Data with ASE EF Severity Categories Established by Ultrasound Echocardiography
Measured over Through study completion, average of 9 months.
Ventricular Ejection Fraction
LVF
LV Dysfunction
Atrial Enlargement
Conduction Defect
Heart Failure
Valvular Heart Disease
Ischemic Heart Disease
Cardiotoxicity
Myocardial Infarction
Dilated Cardiomyopathy
HFrEF - Heart Failure With Reduced Ejection Fraction
HFpEF - Heart Failure With Preserved Ejection Fraction
Syncope
Remodeling, Cardiac

NCT06699056

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hackensack University Medical Center

    Hackensack, New Jerseystudy coordinator listed

    Recruiting

  • Henry Ford Hospital

    Detroit, Michiganstudy coordinator listed

    Recruiting

  • Moses H. Cone Memorial Hospital

    Greensboro, North Carolinastudy coordinator listed

    Recruiting

  • Mount Sinai Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Orange County Heart Institute

    Orange, Californiastudy coordinator listed

    Recruiting

  • Peerbridge Health

    Pasadena, Californiastudy coordinator listed

    Recruiting

  • South Heart Clinic

    Weslaco, Texasstudy coordinator listed

    Recruiting

  • Texas Cardiac Arrhythmia Research Foundation

    Austin, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Andrea Natale, MD · PRINCIPAL_INVESTIGATOR · Texas Cardiac Arrhythmia Research Foundation
  • Johanna P Contreras, MD · PRINCIPAL_INVESTIGATOR · MOUNT SINAI HOSPITAL
  • Sachin Parikh, MD · PRINCIPAL_INVESTIGATOR · Henry Ford Hospital
  • Brian Kolski, MD · PRINCIPAL_INVESTIGATOR · Orange County Heart Institute
  • Daniel Bensimhon, MD · PRINCIPAL_INVESTIGATOR · Moses H. Cone Memorial Hospital
  • Sandeep Gulati, PhD · PRINCIPAL_INVESTIGATOR · Peerbridge Health, Inc
  • Frank Mazzola, MD · PRINCIPAL_INVESTIGATOR · South Heart Clinic
  • Sameer Jamal, MD · PRINCIPAL_INVESTIGATOR · Hackensack Meridian Health
  • Andrea Natale, MD · PRINCIPAL_INVESTIGATOR · HCA Los Robles Hospital & Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Able and eligible to wear a Holter monitor

Exclusion

Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1
Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant
History of poor tolerance or severe skin reactions to ECG adhesive materials
  • Agreement of CorEFS Software EF Severity Categories Using Peerbridge COR™ ECG Data with ASE EF Severity Categories Established by Ultrasound EchocardiographyThrough study completion, average of 9 months.

    The primary endpoint of this trial is to demonstrate substantial agreement between EF severity categories determined by the CorEFS Software using 5 minutes of Peerbridge COR™ ECG data and the subject's EF severity category established through ultrasound echocardiography, the gold standard for EF classification. The study includes four co-primary endpoints, representing agreement measures within each of the four EF severity categories defined by the American Society of Echocardiography (ASE) Scale (Normal, Mildly Abnormal, Moderately Abnormal, Severely Abnormal). For each category the endpoint is the proportion of participants correctly classified by the test device relative to the reference standard. The goal is to demonstrate at least 80% agreement within each EF severity category.